tirzepatide fda obesity grants fast track designation to tirzepatide, Eli Lilly's new type 2 diabetes drug, for treating FDA says that the GLP-1

This steady, sustainable weight loss is a hallmark of GLP-1 medications effectiveness, as it allows the body to adapt to the changes without causing undue stress or nutrient deficiencies

Furthermore, a phase 2 study of semaglutide is not yet recruiting (NCT03659682), and a phase 2 trial of liraglutide demonstrated improvement in non-motor symptoms and activities of daily living (ADL) but failed to show significant differences in motor and cognitive status versus placebo [169]

But with so many people now turning to GLP-1s for help, theres a growing shift toward setting different types of exercise-related goals

Furthermore, everyones body reacts differently to medications

Lastly, significant downregulation of metabolic pathways such as bile acid metabolism, glycolysis, fatty acid metabolism, and oxidative phosphorylation could contribute to tumor suppression by regulating anti-tumor immunity and tumor growth (Fig